

9th August 2024

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051.

Script Code: 500259

Script Code: LYKALABS

Dear Sir/Madam,

Sub.: Outcome of Board Meeting held on 9th August 2024

In Compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; this is to inform you that the Board of Directors at its Meeting held today i.e. 9th August 2024 *inter alia* considered and approved Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2024 together with the Limited Review Reports thereon.

The said Financial Results along with Limited Review Report are attached herewith.

The meeting of the Board of Directors commenced at 12:30 p.m. and concluded at 01:15 p.m.

We request you to take the above information on your record.

Thanking You,

Yours faithfully,
For Lyka Labs Limited

Kishore P. Shah
Company Secretary & Compliance Officer

Encl.: A/a.

Statement of Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2024

(₹ in lakh)

Particulars	Quarter Ended			Year Ended
	30th June 2024 (Unaudited)	31st March, 2024 (Audited)	30th June 2023 (Unaudited)	31st March, 2024 (Audited)
I. Revenue				
Revenue from Operations	3010.47	2698.42	2123.70	10639.63
Other Income	61.95	38.95	42.83	164.72
II. Total Income	3072.42	2737.37	2166.53	10804.35
III. Expenses				
(a) Cost of Materials Consumed	777.53	863.76	609.42	3214.31
(b) Purchase of Stock in trade	400.09	267.69	360.19	1158.47
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(28.09)	9.17	(112.31)	(78.61)
(d) Employee benefits expense	803.50	714.62	566.57	2601.46
(e) Finance Costs	65.07	103.50	133.33	479.79
(f) Depreciation and amortisation expense	167.70	277.17	333.54	1228.71
(g) Other expenses	652.05	621.63	444.07	2287.95
Total Expenses	2837.85	2857.54	2334.81	10892.08
IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)	234.57	(120.17)	(168.28)	(87.73)
V. Exceptional Items (Net)	0.00	0.99	0.00	5.51
VI. Profit / (Loss) before Tax	234.57	(121.16)	(168.28)	(93.24)
VII. Tax Expenses				
Current Tax	40.00	35.47	23.50	159.97
Deferred Tax	19.61	5.49	(19.79)	(26.32)
VIII. Net Profit / (Loss) after Tax	174.96	(162.12)	(171.99)	(226.89)
IX. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)	0.00	10.88	(1.57)	6.17
X. Total Comprehensive Income / (Loss)	174.97	(151.23)	(173.56)	(220.72)
Paid up Equity Share Capital (Face value ₹ 10/- each)	3569.00	3309.00	3309.00	3309.00
Other Equity				6623.91
XI. Basic and diluted earnings per share	0.49	0.50	(0.54)	(0.72)

Notes:

- The above unaudited standalone financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 09th August 2024
- During the quarter ended June, 2024, balance 26,00,000 convertible warrants were converted into equity shares, on receipt of balance amount of 75% of the issue price of Rs.139.50 (including premium) per warrant. Further, such 26,00,000 equity shares were issued and allotted to Ipca Laboratories Limited. Accordingly, our Equity Capital and Securities Premium shall stand increased.
- The Company operates in one business segment i.e. "Pharmaceuticals".
- The figures for the previous year have been regrouped / rearranged wherever considered necessary.
- The Statutory Auditors have expressed an unqualified opinion on the unaudited Standalone financials results for the quarter ended 30th June, 2024.



For Lyka Labs Limited

 Kunal Gandhi
 Managing Director & CEO
 DIN: 01516156

Mumbai : 9th August, 2024.



D. KOTHARY & CO.


Chartered Accountants

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Lyka Labs Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Lyka Labs Limited (the "Company") for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W


Deepak O. Narsaria
(Partner)
Membership No. 121190

UDIN: 24121190BKBOU16974

Place: Mumbai
Date: 9th August, 2024



Statement of Consolidated Unaudited Financial Results for the Quarter Ended 30th June, 2024				
Particulars	Quarter Ended			Year ended
	30th June, 2024	31st March, 2024	30th June, 2023	31st March, 2024
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue				
Revenue from Operations	3,011.40	2,776.73	2,287.70	11,119.46
Other Income	55.88	29.09	37.56	145.47
II. Total Income	3,067.28	2,805.82	2,325.26	11,264.93
III. Expenses				
(a) Cost of Materials Consumed	777.53	863.76	609.42	3,214.31
(b) Purchase of Stock in trade	400.75	324.04	453.89	1,349.36
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(28.09)	9.44	(112.34)	(78.50)
(d) Employee benefits expense	818.77	722.64	593.52	2,676.54
(e) Finance Costs	64.71	107.35	135.14	489.09
(f) Depreciation and amortisation expense	175.66	289.86	346.69	1,280.18
(g) Other expenses	671.70	654.05	478.79	2,386.27
Total Expenses	2,881.03	2,971.14	2,505.11	11,317.25
IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)	186.25	(165.32)	(179.85)	(52.32)
V. Exceptional Items (Net)	-	(2.42)	-	41.06
VI. Profit / (Loss) before Tax	186.25	(162.90)	(179.85)	(93.37)
VII. Non Controlling Interest	(15.06)	4.01	(8.42)	(13.12)
VIII. Profit / (Loss) before Tax	201.31	(166.91)	(171.43)	(80.25)
IX. Tax Expenses				
Current Tax / Earlier Year Tax	40.00	34.36	34.31	186.93
Deferred Tax	17.30	11.50	(21.07)	(18.26)
X. Net Profit / (Loss) after Tax	144.01	(212.77)	(184.67)	(248.92)
XI. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)	(0.34)	11.77	(1.57)	10.54
XII. Total Comprehensive Income / (Loss)	143.67	(201.00)	(186.24)	(238.38)
XIII. Paid up Equity Share Capital (Face value Rs.10/- each)	3,569.00	3,309.00	3,309.00	3,309.00
Other Equity				3,506.43
XIV. Basic and diluted earnings per share	0.40	(0.68)	(0.57)	(0.79)
Notes:				
1.The above unaudited consolidated financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 09th August, 2024.				
2.During the quarter ended June, 2024, balance 26,00,000 convertible warrants were converted into equity shares, on receipt of balance amount of 75% of the issue price of Rs.139.50 (including premium) per warrant. Further, such 26,00,000 equity shares were issued and allotted to Ipca Laboratories Limited. Accordingly, our Equity Capital and Securities Premium shall stand increased.				
3.The Company operates in one business segment i.e. "Pharmaceuticals".				
4. The figures for the previous year have been regrouped / rearranged wherever considered necessary.				
5. The Statutory Auditors have expressed an unqualified opinion on the unaudited Consolidated financials results for the quarter ended 30th June, 2024.				
				
			For Lyka Labs Limited Anil Gandhi Managing Director & CEO DIN: 01516156	
				Mumbai; 09th August 2024



D. KOTHARY & CO.

Chartered Accountants

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Lyka Labs Limited

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of Lyka Labs Limited (the "Parent"), which includes its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. The Statement includes the results of following entities:
Subsidiaries
 - i) Lyka BDR International Limited
 - ii) Lyka Exports Limited
5. The accompanying statement includes the interim financial results and other financial information in respect of 2 subsidiaries, whose interim financial results/information reflects total revenues of Rs. 9.52 lakhs, total net Profit/ (Loss) after tax of Rs. (46.00) lakhs for the quarter ended June 30, 2024, total comprehensive income of Rs. (46.34) lakhs which have been reviewed by us.





D. KOTHARY & CO.

Chartered Accountants

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W

Deepak O. Narsaria
(Partner)
Membership No. 121190



UDIN: 24121190BKBOUU4650 .

Place: Mumbai
Date: 9th August, 2024